Dismiss Alert

Flu Season Hospital Visitor Limitations

Temporary limitations are in place for hospital visitors. Visitors must be 18 years or older and not exhibit any flu symptoms.

Make an Appointment

Meet Our Providers

View Our Locations

 

Cancer Center

Adult Open Studies

Biology

LLUCC-BIOSPECIMEN LABORATORY - SPECIMEN COLLECTION
Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection Protocol
Mark E. Reeves, MD, PhD

Brain

SWOG-NRG-BN001
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT02179086
Joseph Kang, MD
Investigator Initiated-AXUMIN
Differentiating glioma recurrence from treatment-induced necrosis using 18F-fluciclovine (anti-18f-facbc) PET and Multiparametric MR Imaging
https://clinicaltrials.gov/ct2/show/NCT03925675
Warren Boling, MD

Breast

NSABP-B51
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT01872975
Sharon Lum, MD
Investigator Initiated GRASP-CIPN
A Pilot Study of Intraneural Facilitation for Managing Chemotherapy-Induced Peripheral Neuropathy.
https://clinicaltrials.gov/ct2/show/NCT03272919
Gayathri Nagaraj, MD
SWOG-S1418-BR006
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy Cancer
https://clinicaltrials.gov/ct2/show/NCT02954874
Gayathri Nagaraj, MD
SWOG-BR004
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03199885
Gayathri Nagaraj, MD
NIH NIMHD-IGF II (Resvida)
Mechanisms in IGF-II induced Chemoresistance and Mitochondrial regulation in TNB
Gayathri Nagaraj, MD

Germ Cell

COG-AGCT1532
A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with Intermediate and poor-risk metastatic germ cell tumors
https://clinicaltrials.gov/ct2/show/NCT02582697
John Wong, MD

GI

Bowel

SWOG-S1316
Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction
https://clinicaltrials.gov/ct2/show/NCT02270450
Maheswari Senthil, MD

Colon

SWOG-S0820
Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification
https://www.clinicaltrials.gov/ct2/show/NCT03365882
Chung-Tsen Hsueh, MD, PhD
SWOG-S1613
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
https://www.clinicaltrials.gov/ct2/show/NCT01349881
Chung-Tsen Hsueh, MD, PhD

Esophagus

Radiation Medicine
A phase II trial of proton-chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer
https://clinicaltrials.gov/ct2/show/NCT01684904
Gary Yang, MD

Gastric

Astellas-8951-CL-0301
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03504397
Chung-Tsen Hsueh, MD, PhD

Liver

Radiation Medicine
Phase I/II Trial of Stereotactic Body Proton Therapy (SBPT) for Patients with Liver Metastases
https://clinicaltrials.gov/ct2/show/NCT01697371
Gary Yang, MD
QED-QBGJ398-301
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial
https://clinicaltrials.gov/ct2/show/NCT03773302
Chung-Tsen Hsueh, MD, PhD

Pancreas

Investigator Initiated
A Phase II Trial of Pre-operative Chemotherapy (with Gemcitabine and Nab-paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients with Resectable Pancreatic https://clinicaltrials.gov/ct2/show/NCT03492671
Naveenraj Solomon, MD

GU

Prostate

Radiation Medicine
A prospective comparative study of outcomes with proton and photon radiation in prostate cancer
https://clinicaltrials.gov/ct2/show/NCT00831623
Jerry Slater, MD

GYN

Multiple

Investigator Initiated-Paclitaxel
Conventional prophylactic regimen of oral dexamethasone versus short-course intravenous dexamethasone in preventing paclitaxel-related hypersensitivity reactions in gynecologic-oncology patients: A prospective, randomized, open-label study
https://clinicaltrials.gov/ct2/show/NCT03598426
Linda Hong, MD

Ovarian

Investigator Initiated HIPEC
Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT02672098
Mazdak Momeni, MD

Cervical

GOG-0263
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
https://clinicaltrials.gov/ct2/show/NCT01101451
Yevgeniya Ioffe, MD

Urethra

Adelphi Values-VK8373AUS
Patient Experience in Treatment for Low-grade Upper Tract Urothelial Carcinoma
Brian Hu, MD

Uterine

GOG-0238
A Randomized Trial Of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin In Patients With Pelvic-Only Recurrence Of Carcinoma Of The Uterine Corpus
https://clinicaltrials.gov/ct2/show/NCT00492778
Linda Hong, MD

Head and Neck

Soligenix-IDR-OM-02
A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
https://clinicaltrials.gov/ct2/show/NCT03237325
Huynh Cao, MD

Lung

SWOG-A151216
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
https://clinicaltrials.gov/ct2/show/NCT02194738
Hamid Mirshahidi, MD
SWOG-A081105
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
https://clinicaltrials.gov/ct2/show/NCT02194738
Hamid Mirshahidi, MD
SWOG-E4512
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
https://clinicaltrials.gov/ct2/show/NCT02201992
Hamid Mirshahidi, MD
SWOG-LUNGMAP
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
http://clinicaltrials.gov/ct2/show/NCT02154490
Hamid Mirshahidi, MD
Novartis-CACZ885V2301
A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects with non-small cell lung cancer (NSCLC) previously treated with PD(L)1 inhibitors and platinum-based chemotherapy (CANOPY-2)
https://clinicaltrials.gov/ct2/show/NCT03626545
Hamid Mirshahidi, MD

Melenoma

SWOG-S1801
A Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma (NCT #03698019)
https://clinicaltrials.gov/ct2/show/NCT03698019
Mark E. Reeves, MD, PhD

Multiple

SWOG-EAY131-MATCH
Molecular Analysis for Therapy Choice (MATCH)
https://clinicaltrials.gov/ct2/show/NCT02465060
Gayathri Nagaraj, MD
SWOG-S1609
DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
https://clinicaltrials.gov/ct2/show/NCT02834013
John Wong, MD
COG-AGCT1532
A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with Intermediate and poor-risk metastatic germ cell tumors
https://clinicaltrials.gov/ct2/show/NCT02582697
John Wong, MD

Soft Tissue Sarcoma

Radiation Medicine
A phase II study of preoperative proton therapy in soft tissue sarcomas of the extremities and body wall
https://clinicaltrials.gov/ct2/show/NCT01819831
Gary Yang, MD

Registry

Radiation Medicine
Radiation Medicine Patient Registry
https://clinicaltrials.gov/ct2/show/NCT02436941
Jerry Slater, MD
Penn State-Colon Registry
Prospective observational database of patients with colon cancer at risk of peritoneal recurrence
Maheswari Senthil, MD

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050

 

Breakthrough Spinal Tumor Removal

When lung cancer caused a tumor on Dave’s spine, his surgeon used spinal tumor ablation with radiofrequency to remove it and restore his spine to health.

Read Story